Anthropic Unveils Claude Science, Aims to Build AI-Driven Preclinical Drug Programs

On June 30 2026, Anthropic introduced Claude Science at a San Francisco “AI for Science” briefing. The workbench unifies more than 60 scientific databases—including UniProt, PDB, Ensembl, ClinVar, ChEMBL and GEO—into a natural-language interface that retrieves literature, processes data, generates code, creates figures and drafts manuscript text, while recording an auditable history for each output.

Anthropic Unveils ‘Claude Science’ AI Research Platform, Aiming to Compress a Decade of Progress into a Year — BigGo Finance

AI tools are now common in drug discovery, with firms such as OpenAI, Google DeepMind, Insilico Medicine and Isomorphic Labs offering target-identification services. Anthropic, led by life-sciences head Eric Kauderer-Abrams, partnerships chief Jonah Cool and CEO Dario Amodei, recently bought Coefficient Bio for $400 million and added Novartis CEO Vas Narasimhan to its board.

The Verge

Anthropic says Claude Science can accelerate target identification and hypothesis generation, potentially shortening preclinical cycles. Yet no AI-designed drug has yet completed clinical trials, and typical development takes a decade. Todd, a life-science researcher, warned that “there’s always a big lag time… it takes time to show experimentally that something’s safe.” CEO Amodei added that the biological domain lacks the social awareness of AI risks seen in cybersecurity.

Anthropic Unveils ‘Claude Science’ AI Research Platform, Aiming to Compress a Decade of Progress into a Year — BigGo Finance

The Allen Institute used Claude Science to draft a comprehensive review manuscript in weeks, a task that previously required nearly two years. Northeastern University scientist Michael Pollastri said the tool could “increase the pace of our experimentation by orders of magnitude.” Former Novo Nordisk advisor Lotte Bjerre Knudsen noted work that took four years could be done in one.

Anthropic Unveils ‘Claude Science’ AI Research Platform, Aiming to Compress a Decade of Progress into a Year — BigGo Finance

Anthropic has not disclosed which neglected diseases it will target, nor whether it will license candidates, partner for animal testing, or pursue its own clinical trials. The timeline for a market-ready drug is unspecified, and sources differ on Claude Science’s current deployment status.

ZME Science

• “We’re doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you.” — Eric Kauderer-Abrams, Head of Life Sciences, Anthropic

Anthropic launches AI tool to speed up drug discovery

• “These are areas that normal drug development economics don’t incentivize or favor,” — Jonah Cool, Head of Life Sciences Partnerships and Deployment, Anthropic

ZME Science

• “If technological advancement, adaptation in the research field, and regulatory changes happen together, an era will come where we can achieve a decade's worth of scientific progress in a single year. I expect that within the next year, we will see meaningful cases of AI discovering new drug targets.” — Dario Amodei, CEO, Anthropic

Anthropic Unveils ‘Claude Science’ AI Research Platform, Aiming to Compress a Decade of Progress into a Year — BigGo Finance

• “Work that took 4 years could be done in 1” — Lotte Bjerre Knudsen, former Chief Scientific Advisor, Novo Nordisk

Anthropic Unveils ‘Claude Science’ AI Research Platform, Aiming to Compress a Decade of Progress into a Year — BigGo Finance

Anthropic plans to launch its first preclinical projects within twelve months and will create a trust-based access program for biological applications. Early results from neglected-disease pipelines will be published as the platform matures.

ZME Science